SECURITIES AND EXCHANGE COMMISSION

Form 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended December 31, 2004

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to
Commission file number 0-14902

MERIDIAN BIOSCIENCE, INC.

3471 River Hills Drive
Cincinnati, Ohio 45244
(513) 271-3700

Indicate by a check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ   No o

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes þ   No o

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Page 1 of 20

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES
INDEX TO QUARTERLY REPORT ON FORM 10-Q

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should”, and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update any forward-looking statements. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ, including, without limitation, the following: Meridian’s continued growth depends in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration and other governmental bodies can result in unanticipated expenses, delays, and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can change expected results. One of Meridian’s main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian’s operations.

Page 2 of 20

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

The accompanying notes are an integral part of these consolidated financial statements.

Page 3 of 20

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

The accompanying notes are an integral part of these consolidated financial statements.

Page 4 of 20

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

ASSETS

The accompanying notes are an integral part of these consolidated financial statements.

Page 5 of 20

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES
Consolidated Balance Sheets (Unaudited)
(dollars in thousands)

LIABILITIES AND SHAREHOLDERS’ EQUITY

The accompanying notes are an integral part of these consolidated financial statements.

Page 6 of 20

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

The accompanying notes are an integral part of these consolidated financial statements.

Page 7 of 20

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

1. Basis of Presentation:

The consolidated financial statements included herein have not been audited by an independent registered public accounting firm, but include all adjustments (consisting of normal recurring entries), which are, in the opinion of management, necessary for a fair presentation of the results for such periods.

Certain information and footnote disclosure normally included in financial statements prepared in accordance with generally accepted accounting principles has been omitted pursuant to the requirements of the Securities and Exchange Commission, although Meridian believes that the disclosures included in these financial statements are adequate to make the information not misleading.

It is suggested that these consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto, included in Meridian’s Annual Report on Form 10-K for the Year Ended September 30, 2004.

The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year.

2. Significant Accounting Policies:

(a) Foreign Currency Translation -

Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included in a separate component of accumulated other comprehensive income. Revenues and expenses are translated using exchange rates prevailing during the period. Meridian also recognizes foreign currency transaction gains and losses on certain assets and liabilities that are denominated in the Euro currency. These gains and losses are included in other income and expense in the accompanying consolidated statements of operations.

Foreign currency translation is the only component of accumulated other comprehensive income. Comprehensive income for the interim periods ended December 31 was as follows:

Page 8 of 20

(b) Income Taxes -

The provision for income taxes includes federal, foreign, state, and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. Meridian prepares estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of Meridian’s tax returns, which typically occurs in the third and fourth quarters of the current fiscal year for the preceding fiscal year’s estimates.

(c) Stock-based Compensation –

Meridian accounts for its stock-based compensation plans pursuant to the intrinsic value method provided in APB Opinion No. 25. Had compensation cost for these plans been determined using the fair value method provided in SFAS No. 123, Meridian’s net income and earnings per share would have been reduced to the following pro forma amounts (amounts in thousands, except per share data):

(d) Recent Accounting Pronouncements –

During November 2004, the Financial Accounting Standards Board issued Statement No. 151, “Inventory Costs, an amendment of ARB No. 43, Chapter 4”. The standard specifies that idle facility expense, freight, handling costs, and wasted material (spoilage) must be accounted for as current period charges. In addition, the Statement requires that allocation of fixed production overhead be made based upon the normal capacity of the production facilities. This standard is effective for inventory costs incurred during fiscal years beginning after June 15, 2005, which for Meridian would be fiscal year 2006.

During December 2004, the Financial Accounting Standards Board issued a revision of its Statement No. 123, “Accounting for Stock-Based Compensation”. The revised standard requires, among other things, that compensation cost for employee stock options be measured at fair value

Page 9 of 20

on the grant date and charged to expense over the employee’s requisite service period for the option. Due to the absence of observable market prices for employee stock options, the standard indicates that the fair value of most stock options will be determined using an option-pricing model. This standard is effective for public companies for interim and annual periods beginning after June 15, 2005, which for Meridian would be July 1, 2005.

During December 2004, the Financial Accounting Standards Board issued Staff Position No. 109-1, “Application of FASB Statement No. 109, Accounting for Income Taxes, to the Tax Deduction on Qualified Production Activities Provided by the American Jobs Creation Act of 2004”. This staff position states that the qualified production activities deduction should be accounted for as a special deduction in accordance with Statement 109.

In addition, during December 2004, the Financial Accounting Standards Board issued Staff Position No. 109-2, “Accounting and Disclosure Guidance for the Foreign Earnings Repatriation Provision within the American Jobs Creation Act of 2004”. This staff provision dictates that a practical exception exists to the Statement 109 requirement to reflect in the period of enactment the effect of a new tax law with respect to the special one-time tax deduction of 85 percent of foreign earnings that are repatriated (as defined in the American Jobs Creation Act of 2004). It provides that an enterprise is allowed time after the financial reporting period to evaluate the effect of the American Jobs Creation Act of 2004 on its plan for reinvestment or repatriation of foreign earnings for purposes of applying Statement 109.

Meridian does not expect the impact of adoption of these standards to have a significant effect on its results of operations or financial condition. Meridian is currently evaluating the provisions of the American Jobs Creation Act of 2004, including the provision related to repatriation of foreign earnings. This evaluation is expected to be completed in the third quarter of fiscal 2005. At this time, Meridian has not determined a range of reasonably possible amounts of unremitted earnings that would be considered for repatriation.

(e) Reclassifications –

Certain reclassifications have been made to the prior year financial statements to conform with the current year presentation.

3. Inventories:

Inventories are comprised of the following (amounts in thousands):

4. Segment Information:

Meridian’s reportable operating segments are US Diagnostics, European Diagnostics, and Life

Page 10 of 20

Science. The US Diagnostics operating segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostics test kits in the US and countries outside of Europe, Africa and the Middle East. The European Diagnostics operating segment consists of the sale and distribution of diagnostics test kits in Europe, Africa and the Middle East. The Life Science operating segment consists of manufacturing operations in Memphis, Tennessee and Saco, Maine, and the sale and distribution of bulk antigens, antibodies, and bioresearch reagents domestically and abroad. The Life Science operating segment consists of the Viral Antigens and BIODESIGN subsidiaries, including the protein production laboratory.

Segment information for the quarters ended December 31, 2004 and 2003 is as follows (in thousands):

Transactions between operating segments are accounted for at established intercompany prices for internal and management purposes with all intercompany amounts eliminated in consolidation. Total assets for US Diagnostics and Life Science include goodwill of $1,825,000 and $3,598,000, respectively, at December 31, 2004 and September 30, 2004.

5. Intangible Assets:

A summary of Meridian’s acquired intangible assets subject to amortization, as of December 31, 2004 and September 30, 2004 is as follows (in thousands):

Page 11 of 20

The actual aggregate amortization expense for these intangible assets for the three months ended December 31, 2004 and 2003 was $294,000 and $310,000, respectively.

6. Debenture Conversion and Redemption Transactions:

As of September 30, 2004, Meridian had outstanding $16,000,000 convertible subordinated debentures. These debentures are convertible, at the option of the holder, into common stock at prices of $16.09 and $14.50 for the 7% and 5% debentures, respectively. These bonds began converting during the first quarter of fiscal 2005 as the price of Meridian’s common stock reached $18.95 and went on to reach an all time high of $20.56 in January 2005. During December 2004, Meridian also called for redemption $4,000,000 of its 7% debentures. This redemption was completed on January 14, 2005. The actual amount of this redemption was $603,000. The remaining portion was converted to common stock prior to redemption. The following table summarizes the conversion and redemption activity to date (in thousands, except share amounts):

The conversion and redemption transactions noted above are expected to reduce annual interest expense by approximately $514,000.

7. Commitments and Contingencies:

(a) Forward Contracts -

Meridian uses forward contracts from time to time to address foreign currency risk related to certain transactions denominated in the Euro currency. These contracts are used to fix the exchange rate in converting Euros to U.S. Dollars. Gains and losses on such contracts are recorded in other income and expense in the accompanying consolidated statements of operations. As of December 31, 2004, Meridian had three such contracts outstanding with an aggregate notional amount of 900,000 Euros and maturities ranging to April 4, 2005.

(b) OEM Concepts -

On January 19, 2005, Meridian executed a definitive stock purchase agreement to acquire all of the outstanding capital stock of OEM Concepts, Inc., for $6,000,000 in cash and a performance based earn-out opportunity over four years of up to $2,270,000. OEM Concepts is a large-volume producer of monoclonal antibodies that are critical components of commercial diagnostic products used in the diagnosis of infectious diseases and in the monitoring of human protein levels in metabolic disorders, pregnancy, and cardiac disease. This acquisition was completed on January 31, 2005. The purchase price was funded with available cash on hand and proceeds from

Page 12 of 20

Meridian’s revolving credit facility.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Refer to “Forward Looking Statements” following the Index in front of this Form 10-Q.

Current Trends:

US Diagnostics

During the first quarter of fiscal 2005, Meridian launched its ImmunoCard® C. difficile Toxins A & B rapid diagnostic test in domestic markets. Meridian also expects to launch new diagnostic tests for certain respiratory diseases during 2005, upon receiving clearance from the FDA. These tests will broaden Meridian’s product offerings in this category.

European Diagnostics

Sales for Meridian’s European Diagnostics operating segment during the first quarter of fiscal 2005 increased 30% compared to the first quarter of fiscal 2004, partially due to favorable exchange rate fluctuations. Sales in local currency increased 21% for the first quarter of fiscal 2005. The increase in local currency was primarily driven by sales of ImmunoCard® C. difficile Toxins A & B rapid diagnostic test, which was launched in European markets in fiscal 2004, and volume growth for Premier Toxins A & B .

Life Science

During the first quarter of fiscal 2005, the Life Science operating segment began process development and manufacturing of biologicals and biopharmaceuticals that will be used by scientists in the research and development of new and improved diagnostic tests, vaccines, and therapies against potential agents of bioterrorism and emerging infectious diseases. Revenues from these projects are expected to begin to be recognized in the second and third quarters of fiscal 2005, upon delivery and customer acceptance.

On January 19, 2005, Meridian executed a definitive stock purchase agreement to acquire all of the outstanding capital stock of OEM Concepts, Inc., for $6,000,000 in cash and a performance based earn-out opportunity over four years of up to $2,270,000. OEM Concepts is a large-volume producer of monoclonal antibodies that are critical components of commercial diagnostic products used in the diagnosis of infectious diseases and in the monitoring of human protein levels in metabolic disorders, pregnancy, and cardiac disease. This acquisition was completed on January 31, 2005. The purchase price was funded with available cash on hand and proceeds from Meridian’s revolving credit facility. The annual revenue rate for this acquisition is expected to be $5,000,000 to $6,000,000 for fiscal 2005; earnings per share accretion, after giving effect to purchase accounting adjustments, is expected to be between $0.01 and $0.02 per diluted share. Management expects diluted earnings per share accretion to be between $0.04 and $0.06 for fiscal 2006.

Page 13 of 20

Research and Development

Meridian believes that internally-developed products will continue to be a critical source of sales and sales growth. Research and development efforts are expected to focus on the development of new products and product improvements where Meridian has a dominant market position, or its intellectual property is protected by patents or licenses.

Meridian expects its Life Science operating segment will serve as a key platform for sourcing biologicals and technologies, by acquisition or license, for development of new products for all of Meridian’s operating segments. One of Meridian’s specific strategies in this area is to target biologicals that have commercial product applications across multiple markets, such as human diagnostics, veterinary diagnostics, and therapeutics. This strategy is expected to leverage research and development resources as products can be developed with all three markets in mind, rather than on a market-by-market basis.

Operating Segments:

Meridian’s reportable operating segments are US Diagnostics, European Diagnostics, and Life Science. The US Diagnostics operating segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the US and countries outside of Europe, Africa and the Middle East. The European Diagnostics operating segment consists of the sale and distribution of diagnostic test kits in Europe, Africa and the Middle East. The Life Science operating segment consists of manufacturing operations in Memphis, Tennessee and Saco, Maine, and the sale and distribution of bulk antigens, antibodies and bioresearch reagents domestically and abroad. The Life Science operating segment consists of the Viral Antigens and BIODESIGN subsidiaries, including the protein production laboratory.

Results of Operations:

Three Months Ended December 31, 2004 Compared to Three Months Ended December 31, 2003

Net sales

Overall, net sales increased 4% to $18,842,000 for the first quarter of fiscal 2005 compared to the first quarter of fiscal 2004. Net sales for the US Diagnostics operating segment decreased $1,325,000, or 10%, for the European Diagnostics operating segment increased $987,000, or 30%, and for the Life Science operating segment increased $1,014,000, or 60%.

For the US Diagnostics operating segment, the sales decrease was primarily related to respiratory products (decreased $1,343,000), proficiency products (decreased $347,000), and H. pylori products (decreased $217,000), partially offset by sales increases for specimen transport products (increased $355,000) and C. difficile products (increased $220,000). The decrease in sales of respiratory products was driven by timing of the influenza season. The influenza season fully emerged during the first quarter of fiscal 2004, whereas it has not yet fully emerged during the current season. Meridian’s respiratory products include diagnostic tests for influenza, RSV, and mycoplasma. The decrease in sales of proficiency products resulted from the timing of shipments. Also contributing to the sales decreases were unfavorable price variances for H. pylori products. The sales decreases for respiratory, proficiency, and H. pylori

Page 14 of 20

products were somewhat offset by volume increases in specimen transport products and C. difficile products.

For the European Diagnostics operating segment, the sales increase includes currency translation gains in the amount of $291,000. Sales in local currency increased 21% for the first quarter of fiscal 2005, following a 7% increase during the last six months of fiscal 2004. The increase in local currency was primarily driven by sales of C. difficile products ($390,000), including ImmunoCard® C. difficile Toxins A & B rapid diagnostic test, which was launched in European markets in fiscal 2004.

For the Life Science operating segment, the sales increase for the first quarter of fiscal 2005 was primarily attributable to volume growth in make-to-order bulk antigens and antibodies. Sales to one customer accounted for 13% and 5% of total sales for the Life Science operating segment for the first quarters of fiscal 2005 and fiscal 2004, respectively.

For all operating segments combined, international sales were $6,462,000, or 34% of total sales, for the first quarter of fiscal 2005, compared to $4,475,000, or 25% of total sales, for the first quarter of fiscal 2004. Combined domestic exports for the US Diagnostics and Life Science operating segments were $2,208,000 for the first quarter of fiscal 2005, compared to $1,208,000 for the first quarter of fiscal 2004. The remaining international sales were generated by the European Diagnostics operating segment.

Gross Profit

Gross profit increased 9% to $11,013,000 for the first quarter of fiscal 2005 compared to the first quarter of fiscal 2004. Gross profit margins were 58% for the first quarter of fiscal 2005 compared to 56% for the first quarter of fiscal 2004.

Meridian’s overall operations consist of the sale of diagnostic test kits for various disease states and in alternative test formats, as well as bioresearch reagents, bulk antigens, proficiency tests, and contract manufacturing activities in the protein production laboratory. Product sales mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.

Operating Expenses

Operating expenses increased 8% to $7,546,000, for the first quarter of fiscal 2005 compared to the first quarter of fiscal 2004. The overall increase in operating expenses for the first quarter of fiscal 2004 is discussed below.

Research and development expenses decreased 14% to $833,000 for the first quarter of fiscal 2005 compared to the first quarter of fiscal 2004, and as a percentage of sales, decreased from 5% for the first quarter of fiscal 2004, to 4% for the first quarter of fiscal 2005. Of this decrease, $43,000 related to the US Diagnostics operating segment and $96,000 related to the Life Science operating segment.

Selling and marketing expenses increased 9% to $3,316,000 for the first quarter of fiscal 2005 compared to the first quarter of fiscal 2004, and as a percentage of sales, increased from 17% for the first quarter of fiscal 2004 to 18% for the first quarter of fiscal 2005. Of this increase, $93,000

Page 15 of 20

related to the US Diagnostics operating segment, $105,000 related to the European Diagnostics operating segment and $74,000 related to the Life Science operating segment. The increase for the US Diagnostics operating segment was primarily attributable higher salaries and benefits costs ($109,000), including the hiring of a Vice President of Sales and Marketing in January 2004, and costs of promotional materials ($149,000), somewhat offset by lower sales commissions ($170,000) related to lower respiratory product sales. The increase for the European Diagnostics operating segment was primarily due to currency translation. The increase for the Life Science operating segment was primarily attributable to sales commissions and business development costs.

General and administrative expenses increased 15% to $3,397,000 for the first quarter of fiscal 2005 compared to the first quarter of fiscal 2004, and as a percentage of sales, increased from 16% for the first quarter of fiscal 2004, to 18% for the first quarter of fiscal 2005. Of this increase, $384,000 related to the US Diagnostics operating segment, $13,000 related to the European Diagnostics operating segment and $47,000 related to the Life Science operating segment. The increase for the US Diagnostics operating segment was primarily attributable to higher salaries and benefits costs for the first quarter of fiscal 2005 ($74,000), higher accruals for the Company’s corporate incentive plan ($79,000), and increased legal and professional fees, primarily related to the audit of the Company’s financial statements and compliance with the Sarbanes-Oxley Act ($156,000).

Operating Income

Operating income increased 10% to $3,467,000 for the first quarter of fiscal 2005, as a result of the factors discussed above.

Other Income and Expense

Interest expense declined 21% to $290,000 for the first quarter of fiscal 2005 compared to the first quarter of fiscal 2004. This decrease was primarily attributable to lower overall debt levels outstanding for the revolving credit facility and bank term debt, as well as the effects of the exchange and redemption transactions related to the 7% convertible debentures completed in the second quarter of fiscal 2004.

Income Taxes

The effective rate for income taxes was 34% for the first quarter of fiscal 2005 compared to 36% for the first quarter of fiscal 2004. The decline in the effective tax rate was primarily attributable to federal and state credits for research and development activities, state tax credits for various incentives in Ohio, and additional benefits related to non-US sales activities. For the fiscal year ending September 30, 2005, Meridian expects the effective tax rate to approximate 37%.

Liquidity and Capital Resources:

Comparative Cash Flow Analysis

Meridian’s operating cash flow and financing requirements are determined by analyses of operating and capital spending budgets and consideration of acquisition plans. Meridian has historically maintained line of credit availability to respond to acquisition opportunities quickly.

Page 16 of 20

Net cash provided by operating activities increased 4% to $3,842,000 for the first quarter of fiscal 2005, compared to the first quarter of fiscal 2004. This increase was driven by higher net income levels for the first quarter of fiscal 2005.

Net cash used for investing activities was $657,000 for the first quarter of fiscal 2005, compared to $638,000 for the first quarter of fiscal 2004, and related to capital expenditures during both periods.

Net cash used for financing activities was $413,000 for the first quarter of fiscal 2005, compared to $2,195,000 for the first quarter of fiscal 2004. Repayments of debt obligations, including the revolving credit facility, were $263,000 for the first quarter of fiscal 2005 and $1,241,000 for the first quarter of fiscal 2004, reflecting lower debt levels owed by the Company. There were no borrowings outstanding on the revolving credit facility during the first quarter of fiscal 2005, which, in turn, reduced the amount of overall repayments. Proceeds from the exercise of stock options were $1,364,000 for the first quarter of fiscal 2005, compared to $685,000 for the first quarter of fiscal 2004, reflecting Meridian’s increased stock price.

Net cash flows from operating activities are anticipated to fund working capital requirements, debt service, and dividends during fiscal 2005.

Capital Resources

Meridian has a $25,000,000 credit facility with a commercial bank. This facility includes $2,500,000 of term debt and capital lease capacity and a $22,500,000 revolving line of credit that expires in September 2007. As of January 31, 2005, there were $3,904,000 of borrowings outstanding on the line of credit portion of this facility. These borrowings were used to fund a portion of the purchase price for the OEM Concepts acquisition.

As of September 30, 2004, Meridian had outstanding $16,000,000 convertible subordinated debentures. These debentures are convertible, at the option of the holder, into common stock at prices of $16.09 and $14.50 for the 7% and 5% debentures, respectively. These bonds began converting during the first quarter of fiscal 2005 as the price of Meridian’s common stock reached $18.95 and went on to reach an all time high of $20.56 in January 2005. During December 2004, Meridian also called for redemption $4,000,000 of its 7% debentures. This redemption was completed on January 14, 2005. The total amount of this redemption was $603,000. The remaining portion was converted to common stock prior to redemption. The following table summarizes the conversion and redemption activity to date (in thousands, except share amounts):

The conversion and redemption transactions noted above are expected to reduce annual interest expense by approximately $514,000.

Page 17 of 20

Meridian’s bank term debt is denominated in the Euro currency and bears interest at a variable rate tied to Euro LIBOR. A one-percentage point increase in the Euro LIBOR rate would increase fiscal 2005 interest expense by approximately $16,000 for this debt. This debt serves as a natural currency hedge against certain Euro denominated intercompany receivables.

The Viral Antigens acquisition, completed in fiscal 2000, provides for additional purchase consideration up to a maximum remaining amount of $4,804,000, contingent upon Viral Antigens’ future earnings through September 30, 2006. Earnout consideration is payable each year, following the period earned. Earnout payments, if any, may require financing under the line of credit or other bank credit facility. Earnout consideration in the amount of $678,000 related to fiscal 2004 was paid during the second quarter of 2005 from operating cash flows.

Meridian’s capital expenditures are estimated to be $2,500,000 to $3,000,000 for fiscal 2005, and may be funded with operating cash flows or availability under the $25,000,000 credit facility discussed above. Capital expenditures relate to manufacturing and other equipment of a normal and recurring nature.

Recent Accounting Pronouncements:

See Note 2 to the consolidated financial statements contained herein.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Meridian has market risk exposure related to interest rate sensitive debt and foreign currency transactions.

Meridian has debt obligations in the aggregate amount of $16,081,000 outstanding at December 31, 2004, of which $1,711,000 bears interest at variable rates. To date, Meridian has not employed a hedging strategy with respect to interest rate risk.

Meridian is exposed to foreign currency risk related to its European distribution operations, including foreign currency denominated intercompany receivables, as well as Euro denominated term debt. The Euro denominated term debt serves as a natural hedge against a portion of the Euro denominated intercompany receivables.

ITEM 4. CONTROLS AND PROCEDURES

As of December 31, 2004, an evaluation was completed under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rule 13a-15(b) and 15(d)-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2004. There has been no change in the Company’s internal control over financial reporting identified in connection with the evaluation of internal controls that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial

Page 18 of 20

reporting.

PART II. OTHER INFORMATION

ITEM 6. EXHIBITS

10.31 – Stock Purchase Agreement Dated January 19, 2005 Among Meridian Bioscience, Inc. as Purchaser and Robert W. Minarchi, Virginia A. Minarchi, Dianna Chalas and Deborah Colombo as Sellers and OEM Concepts, Inc.

31.1 – Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

31.2 – Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

32.2 – Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Page 19 of 20

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned there-unto duly authorized.

MERIDIAN BIOSCIENCE, INC.

Page 20 of 20